← 產業報告目錄
Oncology Biosimilars Market, By Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Brain Cancer, and Others), By Product Type (Monoclonal Antibodies, Immunomodulators, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
出版商 Coherent Market Insights出版日期 2026-07-30頁數 258報告編號 CMR-97a7e0c4ec
授權報價
| Single User Price | $4,500 USD |
| Site License Price | $7,000 USD |
| Enterprisewide Price (Global Site License) | $10,000 USD |
報告摘要
The Oncology Biosimilars Market is estimated to be valued at USD 9.7 Bn in 2026 and is expected to reach USD 28.5 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 16.6% from 2026 to 2033. The market is undergoing a major transformation owing to the rising prevalence of cancer, increasing demand for affordable biologic therapies, and growing emphasis on expanding access to advanced oncology treatment. Oncology biosimilars including monoclonal antibodies, supportive-care biologics, and therapeutic proteins, enable healthcare systems to reduce treatment costs while maintaining comparable efficacy, safety, quality, and regulatory standards. The market includes a wide array of product applications like breast cancer, colorectal cancer, lung cancer, lymphoma, leukemia, and supportive cancer care.
Patients and healthcare providers are focusing on cost-effective treatment options and broader therapeutic accessibility to improve treatment adherence, ensure continuity of care, and maintain quality of life. Advancements in biologic manufacturing, analytical characterization, and clinical comparability studies are improving product acceptance, especially across hospitals, oncology clinics, and emerging healthcare markets. In addition, the growing use of trastuzumab, bevacizumab, rituximab, pegfilgrastim, and other biosimilar products helps optimize cancer treatment expenditure and patient access, thereby improving clinical outcomes and reducing the overall financial burden on healthcare systems.
Market Dynamics
The market is gaining momentum owing to the increasing global cancer burden, patent expiration of major oncology biologics, and growing pressure to reduce the cost of cancer treatment. Market growth is largely driven by patients, hospitals, oncology centers, and healthcare systems seeking affordable alternatives to reference biologic medicines, particularly for breast cancer, colorectal cancer, lung cancer, non-Hodgkin lymphoma, leukemia, and chemotherapy-induced complications. Comparable clinical efficacy, lower treatment expenditure, expanding regulatory approvals, and increasing physician confidence play a central role in biosimilar adoption, thereby helping broaden treatment access, improve therapy continuity, reduce healthcare spending, and support sustainable cancer care. The rising focus on value-based healthcare, reimbursement optimization, and equitable access to biologic therapies is strengthening demand for oncology biosimilars.
The expiration of exclusivity rights for blockbuster biologics is fueling market growth. This is mainly driven by increasing availability of biosimilar versions of trastuzumab, bevacizumab, rituximab, pegfilgrastim, and filgrastim, alongside greater competition among biologic manufacturers. Product developments involving advanced cell-line engineering, analytical characterization, process optimization, and improved formulation stability help ensure product consistency, meet regulatory comparability requirements, and support reliable therapeutic performance.
The rising demand for cost-efficient cancer care is also propelling the market. Oncologists, hospital pharmacists, regulatory authorities, payers, procurement agencies, biologic manufacturers, and specialty distributors play a crucial role in recommending, approving, purchasing, and supplying oncology biosimilars. As cancer treatment becomes increasingly affordability-focused, the market is expected to benefit from broader reimbursement coverage, stronger tender participation, improved physician education, expanding manufacturing capacity, and the introduction of accessible, clinically comparable, and high-quality biosimilar therapies.
Key Features of the Study
• This report provides in-depth analysis of the Oncology Biosimilars Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Oncology Biosimilars Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Oncology Biosimilars Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Oncology Biosimilars Market
Market Segmentation
• By Cancer Type (Revenue, USD Bn, 2021-2033)
o Lung Cancer
o Colorectal cancer
o Cervical Cancer
o Breast Cancer
o Kidney cancer
o Stomach cancer
o Brain Cancer
o Others
• By Product Type (Revenue, USD Bn, 2021-2033)
o Monoclonal Antibody
o Immunomodulators
o Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Online Pharmacies
o Retail Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players Insights
o Amgen Inc.
o Allergan, Plc
o Mylan N.V.
o Samsung Bioepis Co., Ltd.
o Teva Pharmaceutical Industries Ltd.
o Pfizer Inc.
o Celltrion Healthcare
o Novartis International AG
o Biogen Idec, Inc.
o Biocon Limited
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Cancer Type
Market Snapshot, By Product Type
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Disease Type Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Oncology Biosimilars Market, By Cancer Type, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Colorectal cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Cervical Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Breast Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Kidney cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Stomach cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Brain Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Oncology Biosimilars Market, By Product Type, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Monoclonal Antibody
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Immunomodulators
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Oncology Biosimilars Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Oncology Biosimilars Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Amgen Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Allergan, Plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Mylan N.V.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Samsung Bioepis Co., Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Celltrion Healthcare
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novartis International AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Biogen Idec, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Biocon Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us
圖表清單 List of Tables & Figures
NA
NA
提及公司
o Amgen Inc.o AllerganPlco Mylan N.V.o Samsung Bioepis Co.Ltd.o Teva Pharmaceutical Industries Ltd.o Pfizer Inc.o Celltrion Healthcareo Novartis International AGo Biogen IdecInc.o Biocon Limited
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們